AU2021280418A1 - Gut microbiota bioactivated PDE4 inhibitor precursors - Google Patents
Gut microbiota bioactivated PDE4 inhibitor precursors Download PDFInfo
- Publication number
- AU2021280418A1 AU2021280418A1 AU2021280418A AU2021280418A AU2021280418A1 AU 2021280418 A1 AU2021280418 A1 AU 2021280418A1 AU 2021280418 A AU2021280418 A AU 2021280418A AU 2021280418 A AU2021280418 A AU 2021280418A AU 2021280418 A1 AU2021280418 A1 AU 2021280418A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- disease
- pharmaceutically acceptable
- alkyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063031023P | 2020-05-28 | 2020-05-28 | |
| US63/031,023 | 2020-05-28 | ||
| PCT/CA2021/050725 WO2021237364A1 (en) | 2020-05-28 | 2021-05-28 | Gut microbiota bioactivated pde4 inhibitor precursors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021280418A1 true AU2021280418A1 (en) | 2023-02-02 |
Family
ID=78745382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021280418A Pending AU2021280418A1 (en) | 2020-05-28 | 2021-05-28 | Gut microbiota bioactivated PDE4 inhibitor precursors |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230250123A1 (https=) |
| EP (1) | EP4157853B1 (https=) |
| JP (1) | JP7762168B2 (https=) |
| KR (1) | KR20230029682A (https=) |
| CN (1) | CN116056713B (https=) |
| AU (1) | AU2021280418A1 (https=) |
| ES (1) | ES2989065T3 (https=) |
| MX (1) | MX2022014416A (https=) |
| WO (1) | WO2021237364A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6200993B1 (en) * | 1999-05-05 | 2001-03-13 | Merck Frosst Canada & Co. | Heterosubstituted pyridine derivatives as PDE4 inhibitors |
| MY123585A (en) * | 2000-03-23 | 2006-05-31 | Merck Canada Inc | Tri-aryl-substituted-ethane pde4 inhibitors. |
| AU2003281219A1 (en) * | 2002-07-02 | 2004-01-23 | Bernard Cote | Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| WO2007142929A2 (en) * | 2006-05-31 | 2007-12-13 | The University Of North Carolina At Chapel Hill | Novel pde4 inhibitors |
-
2021
- 2021-05-28 EP EP21813912.9A patent/EP4157853B1/en active Active
- 2021-05-28 CN CN202180058681.5A patent/CN116056713B/zh active Active
- 2021-05-28 AU AU2021280418A patent/AU2021280418A1/en active Pending
- 2021-05-28 MX MX2022014416A patent/MX2022014416A/es unknown
- 2021-05-28 JP JP2022573665A patent/JP7762168B2/ja active Active
- 2021-05-28 KR KR1020227045933A patent/KR20230029682A/ko active Pending
- 2021-05-28 ES ES21813912T patent/ES2989065T3/es active Active
- 2021-05-28 US US17/927,827 patent/US20230250123A1/en active Pending
- 2021-05-28 WO PCT/CA2021/050725 patent/WO2021237364A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022014416A (es) | 2023-02-22 |
| KR20230029682A (ko) | 2023-03-03 |
| JP7762168B2 (ja) | 2025-10-29 |
| JP2023528397A (ja) | 2023-07-04 |
| EP4157853B1 (en) | 2024-07-31 |
| CN116056713B (zh) | 2025-09-09 |
| US20230250123A1 (en) | 2023-08-10 |
| CN116056713A (zh) | 2023-05-02 |
| ES2989065T3 (es) | 2024-11-25 |
| WO2021237364A1 (en) | 2021-12-02 |
| CA3174137A1 (en) | 2021-12-02 |
| EP4157853A1 (en) | 2023-04-05 |
| EP4157853A4 (en) | 2023-12-13 |
| EP4157853C0 (en) | 2024-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12509466B2 (en) | Methods and compounds for treating paramyxoviridae virus infections | |
| CA2952966C (en) | SUBSTITUTE NUCLEOSIDES, NUCLEOTIDES AND THEIR ANALOGUES | |
| RU2678327C2 (ru) | Производные маннозы для лечения бактериальных инфекций | |
| BR112015014458B1 (pt) | Compostos derivados de manose, seus intermediários, composição, uso e processos de preparação | |
| US20140107049A1 (en) | Mannose derivatives for treating bacterial infections | |
| EP4157853B1 (en) | Gut microbiota bioactivated pde4 inhibitor precursors | |
| CA3174137C (en) | Gut microbiota bioactivated pde4 inhibitor precursors | |
| EP3307733B1 (en) | Mannose derivatives for treating bacterial infections | |
| HK40093996A (zh) | 肠道微生物群生物活性pde4抑制剂前体 | |
| JP2024544615A (ja) | 光線力学療法及び診断 | |
| HK1163109A1 (en) | Bicyclic derivatives of morphine-6-glucuronide, process for their preparation and their application in therapy | |
| OA16300A (en) | Methods and compounds for treating paramyxoviridae virus infections. |